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Immunoproteomics: The Key to Discovery of New Vaccine Antigens 
Against Bacterial Respiratory Infections 
Ruth Dennehy and Siobhán McClean* 
Centre of Microbial Host Interactions, Centre of Applied Science for Health, Institute of Technology Tallaght, Old 
Blessington Road, Dublin 24, Ireland 
Abstract: The increase in antibiotic resistance and the shortage of new antimicrobials to prevent difficult bacterial infec-
tions underlines the importance of prophylactic therapies to prevent infection by bacterial pathogens. Vaccination has re-
duced the incidence of many serious diseases, including respiratory bacterial infections. However, there are many patho-
gens for which no vaccine is available and some vaccines are not effective among all age groups or among immunocom-
promised individuals. Immunoproteomics is a powerful technique which has been used to identify potential vaccine can-
didates to protect against pathogenic bacteria. The combination of proteomics with the detection of immunoreactive anti-
gens using serum highlights immunogenic proteins that are expressed during infection. This is particularly useful when 
patient serum is used as the antigens that promote a humoral response during human infection are identified. This review 
outlines examples of vaccine candidates that have been identified using immunoproteomics and have successfully pro-
tected animals against challenge when tested in immunisation studies. Many immunoreactive proteins are common to sev-
eral unrelated pathogens, however some of these are not always protective in animal immunisation and challenge studies. 
Furthermore, examples of well-established immunogens, including Bordetella pertussis antigen FHA were not detected in 
immunoproteomics studies, indicating that this technology may underrepresent the immunoreactive proteins in a patho-
gen. Although only one step in the pathway towards an efficacious approved vaccine, immunoproteomics is an important 
technology in the identification of novel vaccine antigens.  
Keywords: Antigens, immunoproteomics, immunoreactive proteins, respiratory disease, vaccine, virulence. 
INTRODUCTION 
 The value of vaccination as a means of combating life-
threatening and chronic infectious diseases is well estab-
lished. Many diseases which previously contributed to mor-
tality are now prevented by vaccination. However, according 
to the WHO, about 1.5 million of deaths among children 
under five in 2008 were caused by vaccine preventable dis-
eases. In addition many approved vaccines are more effec-
tive in young children than in adolescents and adults. Given 
that infectious diseases are still the leading global cause of 
morbidity and mortality and when considered in the context 
of both the rise in antimicrobial resistance and the lack of 
novel effective antibiotics in the drug development pipeline 
[1], the need for more efficacious vaccines for bacterial 
pathogens cannot be underestimated.  
 There are several bacterial cell components incorporated 
into subunit vaccines, LPS, glycoconjugated vaccines, DNA 
vaccines, protein vaccines, which in addition to live attenu-
ated vaccines and whole killed cell vaccines stimulate the 
host immune response in a variety of ways. Vaccine studies 
have often focussed on lipopolysaccharide (LPS) due to its 
potent stimulation of the immune response; however the an-
tigenic diversity of the O-antigen component of LPS within 
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species has limited the potential of LPS as potential vaccine 
antigens, for example P. aeruginosa LPS [2]. Many ap-
proved vaccines are glycoconjugate in nature (e.g. vaccines 
for Neisseria meningitidis and Streptococcus pneumoniae) 
and have proved effective against certain serogroups of 
pathogens; but they tend to suffer from the same issues with 
variability across strains. In addition, serotype switching and 
serotype replacement may undermine their effectiveness in 
the future [3]. Proteins are often more conserved across bac-
terial strains and have more potential to protect against sev-
eral strains of the same bacterial species.  
 Investigation and harnessing of the host-pathogen re-
sponse are beneficial to two separate but essential aspects to 
vaccine development. Exploitation of the human humoral 
response by determining immunogenic bacterial protein us-
ing sera from vaccinated, colonised or recovering individuals 
has played an important part in identifying novel vaccine 
antigens. Identification of novel antigens is only part of the 
process of vaccine development, therefore examination of 
the host response in adults and in human volunteers at the 
cellular and humoral response level is also essential in the 
development of more efficacious vaccines. Protection against 
certain intracellular pathogens requires a strong cell-
mediated immune response driven by polarisation towards a 
Th1 response; while other extracellular pathogens are best 
protected by a Th2 response which promotes antibody pro-
duction and antibody-mediated cell killing [4]. Indeed 
knowledge of the interactions between pathogens and host 
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cells in vitro is also critical, where the bacterial components 
that attach to host cells are investigated and elucidated. This 
review will focus on a number of examples of the exploita-
tion of the host response in the identification of novel anti-
gens and in the development of identified vaccine antigens as 
prophylactic therapies against respiratory bacterial diseases.  
EXPLOITING THE MICROBIAL–HOST RESPONSE 
TO IDENTIFY NEW ANTIGENS 
 Reno Rappuoli and co-workers pioneered the use of a 
genomics approach to identify novel antigens against Neisse-
ria meningitidis serogroup B using reverse vaccinology, in 
the late 1990s. They sequenced the genome of the pathogen, 
identified proteins which were likely to be surface associ-
ated, expressed these in Escherichia coli and administered 
the 350 proteins to mice to identify those that were immuno-
genic [5]. The sequencing step of the process took 18 months 
at the time. The development of genomics since then has 
meant a rapid expansion in the capabilities to identify new 
antigens. Over 2,800 bacterial genomes have been com-
pletely sequenced at time of writing, a figure which is in-
creasing week on week (NCBI Microbial genomes: 
www.ncbi.nlm.nih.gov/genome). This vast bank of informa-
tion combined with the advances in proteomics, including, 
the relatively reproducibility and ease of preparing 2-D gels 
has meant a rapid increase in proteomic analysis of bacterial 
pathogens which has given insights into mechanisms of bac-
terial virulence and pathogenesis, adaptation during chronic 
colonisation and host response. The natural step up to im-
munoproteomics, whereby 2-D blots are probed with host 
serum following infection or immunisation has greatly en-
hanced the identification of potential vaccine candidates, by 
enabling the discovery of novel proteins that stimulate the 
humoral host immune system. A key advantage of this ap-
proach is that final expressed bacterial proteins are used in 
the analysis, which have been completely processed and 
post-translationally modified by the pathogen. Several 
groups have used this method to discover potential vaccine 
candidates with varying degrees of success. Different sera 
have been used in these types of studies which range from 
using colonised patient sera, convalescent sera, or sera from 
challenged mice or rabbits. Furthermore, the majority of 
immunoproteomic studies have focussed on cell surface pro-
teins or outer membrane proteins as this subgroup of bacte-
rial proteins represent the interface for host pathogen interac-
tions and regularly include adhesins. Other groups have ex-
amined secreted proteins as they are also primary antigen 
targets of the host immune response and include many viru-
lence factors. Collectively, their exposure to the host im-
mune system marks these pools of proteins as a rich source 
of vaccine candidates. 
Streptococcus Pneumoniae 
 Streptococcus pneumoniae is a Gram positive bacterium 
that is a leading cause of bacterial pneumonia, meningitis 
and pneumococcal septicaemia. It accounts for 20 to 50% of 
community acquired pneumonia cases and is the cause of 
over 820,000 deaths each year in children under five [6]. The 
seven-valent glycoconjugate pneumococcal vaccine Prevnar 
7 has reduced the incidence of invasive pneumococcal dis-
ease in children and mortality from this disease; however, it 
is not optimal for protection in children under two or in im-
munocompromised patients [3]. Furthermore, there has been 
serotype replacement and increased incidence of non-vaccine 
serotypes, including the antimicrobially resistant serotype 
19A, which now predominates in some countries [3]. Al-
though the recently approved 10- and 13-valent vaccines 
target more serotypes and prevent invasive disease in chil-
dren, there are at least 92 serotypes. This means that identifi-
cation of protein antigens which are more highly conserved 
across the species than the capsular polysaccharides may 
present more effective alternatives.  
 Immunoproteomics has been used to identify potential 
immunogenic antigens in S. pneumoniae. Adults develop 
antibodies to S. pneumoniae during asymptomatic carriage 
and it has been shown that the antibody response is age de-
pendent [7,8]. This increase in antibody response to S. 
pneumoniae proteins which correlated with a reduction in 
morbidity in children prompted Ling et al., to focus on anti-
gens which showed increased immunogenicity with age of 
the child [9]. Two-dimensional Western blotting of cell wall 
fractions from S. pneumoniae probed with sera from healthy 
children ranging in age from 18 to 42 months or with sera 
from adults highlighted seventeen immunoreactive proteins. 
Two of these, both metabolic enzymes, were equally protec-
tive against two genetically different strains in a mouse chal-
lenge model. While this indicates promise for the proteomic 
approach to identify protective antigens, the protection ob-
tained was only 36%. Another two antigens identified in this 
study, 6-phosphogluconate dehydrogenase (6-PGD) and Glu-
tamyl-tRNA synthase were subsequently shown to be in-
volved in adhesion to A549 cells [10,11]. While both inde-
pendently protected mice against a lethal challenge, the level 
of protection was only marginally better than that observed 
with GAPDH and Fructose-bis-phosphate aldolase. In the 
case of 6-PGD, immunization also reduced lung and blood 
colonisation levels by several fold. The latter antigen, glu-
tamyl-tRNA synthase shows promise due its lack of a human 
orthologue, the former protein has high homology to the hu-
man orthologue which could be detrimental to its develop-
ment as a protective antigen [11].  
 A separate proteomic analysis of cell wall proteins identi-
fied proteins which were expressed across at least 40 S. 
pneumoniae serotypes and during animal infection [12]. Five 
proteins were evaluated in a mouse sepsis model, and al-
though lung bacterial burdens were reduced following indi-
vidual immunisations with two of the proteins, these did not 
prolong the survival of mice. The poorer outcome in this 
study, compared with that of Ling and co-workers, may be 
due to the fact that immunogenic proteins were not necessar-
ily selected for this study. More recently, immunoproteomic 
analysis of the S. pneumoniae secretome also identified anti-
gens which were shown to be immunogenic using immu-
nised rabbit serum [13]. In total 54 proteins were detected, of 
which only 23 were identified, including several proteins 
which were known virulence factors, in addition to novel 
proteins. These have the potential as diagnostic markers in 
addition to vaccine candidates. Many of these immunogenic 
proteins had been previously identified in other species and 
in some cases by Ling et al., e.g., Enolase, ZmpB, serine 
protease [9]. However, vaccine studies on these have not 
been reported to date.  
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 Overall, the comparable survival rates following lethal 
challenge (36 to 40%) for the four separate antigens de-
scribed above and the lack of improved survival for others 
may suggest that more knowledge of the specific protective 
host response to S. pneumoniae is required to optimise fur-
ther vaccine development. Indeed the finding that four dis-
tinct antigens showed very comparable survival rates may be 
a feature of the animal model used. It is possible that mice 
are not predictive of the immunological response to S. pneu-
moniae in humans. This is a key limitation of pre-clinical 
vaccination studies that must be always considered. An ex-
ample of this is highlighted below in the discussion on Bor-
detella pertussis immunoproteomics studies.  
Burkholderia Pseudomallei and other Members of Genus 
Burkholderia 
 Burkholderia pseudomallei, the causative agent of 
melioidosis, is a Gram-negative, intracellular pathogen en-
demic in Southeast Asia and Northern Australia. The disease 
is considerably variable in humans ranging from acute septi-
caemia, pneumonia to chronic or latent infection which can 
persist and emerge decades later. The bacterium is intrinsi-
cally antibiotic resistant and has a mortality rate up to 50%; 
however despite its significant morbidity and mortality, there 
is currently no licensed vaccine against this infection. Hard-
ing et al., have used serum from convalescent patients to 
probe 2-D blots of B. pseudomallei OMPs [14]. By biotiny-
lation of the bacteria prior to OMP preparation, they were 
able to focus solely on surface expressed proteins. They 
identified nine surface proteins which were immunoreactive, 
including elongation factor Tu (EF-Tu), polyribonucleotide 
nucleotidyl transferase and two chaperones, GroEL and 
DnaK. Among the biotinylated proteins identified were sev-
eral that would be considered to be cytoplasmic. This high-
lights a common theme in proteomic analysis, that proteins 
predicted to be cytoplasmic and without any signal peptide 
are exposed at the bacterial surface [15]. A later study util-
ised rabbit serum to probe 2-D blots of membrane proteins 
and again identified elongation factor Tu (EF-Tu) and DnaK 
among the immunoreactive proteins of a less virulent related 
species, B. thailandensis, which shares 94% identity at the 
amino acid level with B. pseudomallei [16]. EF-Tu was 
shown to be secreted in outer membrane vesicles (OMVs) 
which are shed from B. pseudomallei during in vitro growth. 
Mucosal immunisation of mice with EF-Tu resulted in the 
generation of antigen specific IgG and IgA, polarised Th1 
immune response and significantly reduced the bacterial 
burden in the lungs following a lethal challenge with B. thai-
landensis. OMVs are gaining momentum as a potential vac-
cine platform [17,18]. These are engineered proteoliposomes 
which incorporate the vaccine antigen, adjuvant in a particu-
late carrier. In a later study sub-cutaneous immunisation of 
mice with purified B. pseudomallei OMVs resulted in protec-
tion of 60% of mice against a lethal challenge with high 
OMV-specific titres, together with T-cell responses and hu-
moral responses which were suggestive of a Th1 cell-
mediated immunity [19]. It was not stated whether these pu-
rified OMVs contained EF-Tu or what their antigenic com-
position was.  
 Immunoscreening of a lambda genomic library with 
pooled patient serum represents an alternative way of identi-
fying immunoreactive antigens in B. pseudomallei [20]. This 
functional genomic approach allowed the screening of 5760 
open reading frames which were then used to genetically 
immunise mice. Three clones were selected from an initial 
screen of 14 serum reactive phagemids, based on their strong 
reactivity. Serological evaluation of 74 patients showed that 
94% of patients were seropositive for one of these proteins, 
OmpA. B. pseudomallei have several putative OmpA genes, 
cloning of these resulted in 6 recombinant proteins. Two of 
these were followed up, Omp3 which clustered with the 
OmpA of E. coli and Klebsiella pneumonia OmpA following 
multiple sequence alignment, and Omp7 which was closely 
related to OmpA of Porphyromonas gingivalis [20]. Subse-
quent mouse immunisation with these resulted in 50% pro-
tection against a lethal challenge for two different recombi-
nant OmpA proteins with the most reactivity with sera from 
melioidosis patients [21]. When this pilot immunisation 
study is considered together with the widespread seropositiv-
ity for OmpA among convalescent melioidosis patients, it 
strongly suggest the potential for this antigen as one compo-
nent of a future multi-valent vaccine against melioidosis. 
Using a similar approach, Su et al., carried out a genomic 
survey of B. pseudomallei, screening an expression library 
with sera from melioidosis patients [22]. Among the 109 
proteins identified from seropositive clones, one protein was 
selected, OMP85, for later study, as it is a highly conserved 
protein. Intraperitoneal immunisation of mice with this re-
combinant antigen resulted in 70% protection of mice over 
15 days, as opposed to 10% in non-immunised mice in addi-
tion to significantly reduced bacterial load in lungs and 
spleen [23].  
 Most recently, protein microarrays have been used to 
identify immunoreactive proteins with plasma from recov-
ered melioidosis patients or seropositive healthy individuals 
[24]. Of the 27 antigens identified, seven were more strongly 
recognised by plasma from recovered individuals over 
healthy controls. These represented antigens which were 
previously identified, and/or associated with virulence, in-
cluding flagellin and flagellar hook associated protein, 
OmpA and BipB, confirming the capacity for patient serum 
to identify potential vaccine candidates. Although BipB was 
previously shown not to prolong survival of challenged mice 
[25], antibody levels against OmpA (one of the two OmpAs 
which was also found to be protective by Hara et al. [21]) 
were 10-fold higher in patients that had only one episode of 
melioidosis relative to those with recurrent disease, again 
indicating that antibodies specific to this protein may be pro-
tective. Another closely related pathogen, Burkholderia ce-
pacia is one of 17 closely related species that comprise the 
Burkholderia cepacia complex [26]. This group of pathogens 
are responsible for chronic lung infections in people with 
cystic fibrosis and other immunocompromised individuals. 
The secretory proteins of B. cepacia were analysed on 2-D 
blots probed with serum from immunised mice [27]. One 
protein in particular showed a 96% homology with a metal-
loprotease from a B. pseudomallei strain and it was sug-
gested that this could cross-protect against both pathogens. 
No in vivo challenge experiments were reported.  
 Overall, investigation of immunoreactive proteins in B. 
pseudomallei using immunoproteomics or gene expression 
libraries has already allowed the identification of vaccine 
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candidates to protect against melioidosis, and further identi-
fication of additional antigens should allow the development 
of a multivalent vaccine which will improve protection 
against B. pseudomallei and eliminate bacterial persistence. 
Taking both chronic infection and the intracellular lifestyle 
of B. pseudomallei into consideration, it is evident that there 
will be significant challenges in the development of an effec-
tive vaccine against this agent. A successful vaccine is likely 
to need the induction of both humoral and cell-mediated im-
munity for the complete protection against this pathogen.  
Neisseria meningitidis 
 N. meningitidis colonises the upper respiratory tract, 
causing a mild respiratory infection, however in about 15% 
of patients it invades. There are five serogroups of this Gram 
negative pathogen which causes pneumonia, meningococcal 
meningitis and septicemia. Glycoconjugate vaccines are 
available which are effective against only four serogroups 
and it is widely recognised that the disease can be prevented 
by vaccination to induce antibody dependent complement 
mediated bactericidal activity [28]. No vaccine exists for 
serogroup B, which is responsible for over 30% of meningo-
coccal disease in the US and up to 80% in Europe. In what 
was the first application of reverse vaccinology, several se-
rogroup B antigens were identified which resulted in high 
titres of bactericidal antibodies, including, factor H binding 
protein (fHbp) and Neisserial heparin binding antigen 
(NHBA) [5]. Three highly immunogenic antigens (fHbp, 
Neisseria adhesin (NadA) and NHBA were combined with 
OMVs from an epidemic strain and are currently in phase III 
clinical trials. In contrast to the studies on other pathogens, a 
recent immunoproteomic analysis of Neisseria meningitidis 
failed to identify potentially protective antigens, i.e antigens 
which produced bactericidal antibodies when subsequently 
tested in mice [29]. Sera from both acute and convalescent 
patients were used to probe 2-D blots allowing the identifica-
tion of 33 immunoreactive proteins. Interestingly many of 
the proteins identified were also shown to be immunogenic 
in other respiratory pathogens, e.g. GroEL, elongation factor-
Tu, DnaK and cysteine synthase, but comparison of different 
patient sera indicated that meningococcal patients have very 
variable immune responses against a range of antigens. 
When the recombinant proteins were expressed and adminis-
tered to mice, all sera had significant protein-specific ELISA 
titres, however none of these sera showed bactericidal activ-
ity. Protection of mice against challenge was not reported.  
B. Pertussis 
 Bordetella pertussis is a Gram-negative bacterium re-
sponsible for the highly contagious respiratory infection, 
whooping cough (pertussis), in humans. Pertussis vaccina-
tion exemplifies the benefits of vaccination and the issues 
that arise when vaccine uptake wanes. The whole cell pertus-
sis vaccine had a major impact on reducing childhood mor-
tality when it was introduced in the 1940s, however, serious 
side effects, including encephalitis, in a subgroup of vacci-
nated children led to its reduce uptake and consequent wide-
spread outbreaks throughout the 1970. Introduction of the 
acellular pertussis vaccine improved confidence and conse-
quently uptake of the pertussis vaccination with the effect of 
reducing the incidence among children for the next decade. 
However, while vaccination decreased the incidence of this 
infection, there are reports of a resurgence of pertussis 
among adults and adolescents in recent years, in developed 
countries, despite good uptake of pertussis vaccination [30]. 
The current 5-component acellular vaccine administered in 
combination with diphtheria and tetanus toxoids (DTaP) and 
also combined with Haemophilus influenzae B and polio 
antigens, contains five Bd. pertussis antigens. The antigens 
include pertussis toxoid, filamentous hemagglutinin (FHA), 
fimbriae 2 and 3 and pertactin. These antigens are all viru-
lence factors and play a role in bacterial attachment (re-
viewed by Marzouqi et al. [31], and antibodies to these have 
been identified in infected patients [32]. There is renewed 
interest in improving pertussis vaccination which has led to a 
number of immunoproteomics studies. These, however, 
highlight some limitations of immunoproteomics. Two sepa-
rate studies of Bd. pertussis surface proteins [33] and secre-
tome [34] were carried out using mouse antisera from inacti-
vated Bd. pertussis immunised mice as the primary antibody. 
The surface immunoproteomes for two strains of Bd. pertus-
sis were nearly identical. Among the 27 immunoreactive 
proteins identified across both strains, pertactin which is a 
component of the current approved pertussis vaccine, was 
identified. Interestingly, although FHA is present in the sur-
face proteome and is a highly immunogenic component of 
acellular pertussis vaccines, it was not identified as an im-
munogenic protein among both lab strains examined in this 
study [33]. This may be due to its very large molecular size 
and consequent poor transfer to blotting membranes. An-
other study of immunoreactive proteins in Bd. pertussis ana-
lysed the serum of children that had been immunised with 
the whole cell pertussis vaccine also identified pertactin 
among the immunoreactive proteins, but neither FHA nor 
pertussis toxin. Zhu et al., compared the murine immunopro-
teome with the human immunoproteome of Bd. pertussis and 
found considerable differences in immunoreactivity [35]. 
Only four human immunoreactive proteins were detected 
from immunised or infected mice and many human immu-
nodominant antigens were not recognised by murine immune 
sera. This clearly demonstrates that bacterial antigens may be 
recognised differently by the murine and human immune 
systems and may indicate that researchers should be cautious 
when using murine antisera, or indeed antisera from other 
species, in the identification of potential human vaccine anti-
gens.  
INVESTIGATING THE HOST RESPONSE TO EN-
HANCE THE EFFICACY OF IDENTIFIED ANTI-
GENS: DEVELOPMENT OF A P. AERUGINOSA 
VACCINE 
 The identification of vaccine antigens by immunopro-
teomics or other immunomic analysis, although powerful 
technologies, is only the first step in a long process to suc-
cessful protective vaccine. Indeed, several immunogenic 
proteins identified have failed to protect against challenge in 
subsequent animal models (for example, BipB in B. pseu-
domallei [25] and GroEL and EF-Tu in N. meningitidis [29]. 
A full knowledge of the host response that is required for a 
protective response in humans is essential in the develop-
ment of an effective vaccine. The process involved is exem-
plified by the separate development of vaccine candidates 
against P. aeruginosa. This is an opportunistic pathogen 
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which colonises 80% of adults with the genetically inherited 
disease cystic fibrosis, contributing to the mortality and mor-
bidity of that disease. It is also responsible for a significant 
proportion of ventilator associated pneumonias and colonises 
and invades burn patients causing sepsis. P. aeruginosa 
strains are characterised by intrinsic resistance to a range of 
antimicrobial agents and antibiotics and have multiple 
mechanisms of resistance which means that treatment is dif-
ficult. In susceptible populations, prevention of infection 
would represent a better approach to therapy and indeed, 
prevention of infection with P. aeruginosa is a major objec-
tive in the treatment of chronic obstructive pulmonary dis-
ease and cystic fibrosis. The development of protective vac-
cines to protect susceptible populations against this pathogen 
spans several decades. The majority of the work has fo-
cussed on a limited number of antigens that showed promise 
early in their development. The potential for outer membrane 
protein OprF was first identified as a protective antigen as 
early as 1984 [36] and its suitability confirmed when it was 
demonstrated using a panel of monoclonal antibodies as be-
ing a conserved protein, with several conserved surface epi-
topes [37]. It was evaluated as a hybrid protein with another 
conserved outer membrane protein OprI, which was also 
antigenically cross-reactive against seventeen serogroups 
[38]. This recombinant hybrid protein was subsequently 
shown to protect immunosuppressed mice against P. aerugi-
nosa challenge and was shown to be tolerated in human vol-
unteers [39]. Antibodies against OprF have been shown to be 
protective in burn and ocular models of P. aeruginosa infec-
tion [40,41], however, only partial responses have been 
achieved in cystic fibrosis patients, so the recent focus of 
development of this vaccine antigen has been in understand-
ing the host response and optimising the adjuvant/ vaccine 
administered to maximise the protective response. Investiga-
tion of the host response in chronically colonised CF patients 
has suggested that a Th2 response correlated with infection, 
while a Th1 cell response correlated with an improved out-
come and may be more protective [42,43]. Bumann et al., 
have shown that a live vaccine constructed from a number of 
attenuated Salmonella vaccine strains induced mucosal re-
sponses in human volunteers when administered orally or 
nasally [44]. This phase I/II clinical trial on the OprF-OprI 
conjugate vaccine demonstrated high levels of specific anti-
bodies, including IgA at the bronchial surface and showed 
that the nasal route was superior in terms of mucosal anti-
body response [44]. While this work towards an OprF-OprI 
vaccine to protect children with CF against P. aeruginosa is 
promising, a Phase III randomised control trial will be neces-
sary to determine its efficacy and to demonstrate that anti-
body titres in this case, correspond to protection. An alterna-
tive immunisation approach using adoptive transfer of OprF-
pulsed dendritic cells as the vaccine in a mouse model 
showed significant protection and clearance of P. aeruginosa 
and activation of a Th1 response with a concomitant reduc-
tion in inflammatory cell recruitment. They also observed 
protection against a mucoid strain which is generally associ-
ated with chronic colonisation of the CF lung, albeit a 
slightly delayed response relative to the non-mucoid strain 
[45]. 
 Understanding the host pathogen interaction of these 
vaccines will allow the development of future vaccines 
which protect against different pathogens. Extensive host 
response studies have been carried out on the proteins in-
volved in this OprF-OprI hybrid antigen. OprF has been 
shown to involved in attachment of P. aeruginosa to host 
cells [46] and is upregulated during chronic infection, in con-
trast to other virulence factors which are either lost or down 
regulated [47]. OprF is involved a range of other virulence 
characteristics in P. aeruginosa, including Type III secretion 
system, production of virulence factors such as pyocyanin, 
elastase and exotoxin A and adhesins [46], again illustrating 
the potential of virulence factors and adhesins as protective 
antigens. It has been suggested that OprF is a host immune 
system sensor enabling P. aeruginosa to enhance virulence 
when bacteria are in contact with the host [46].  
 Independently, another aspect of the P. aeruginosa at-
tachment has been exploited, leading to the development of 
flagellin and flagella-based vaccines which have been tested 
in Phase III clinical trials. Most CF patients immunised de-
veloped high serum titres to flagella A and B and a signifi-
cant reduction in the number of immunised patients that de-
veloped P. aeruginosa infection was observed among the 
group of patients that received all four vaccinations [48]. 
Disappointingly, the study did not show a significant reduc-
tion in chronic infection in these patients, or an alteration in 
the rate of decline in lung function. In a follow-on analysis 
of the immune response to vaccination, Campodonico et al., 
showed that the polymeric flagella rather than monomeric 
flagellin appeared to be superior for generating immunity to 
P. aeruginosa. Antibodies to type a and b flagella were more 
potent in mediating opsonic killing of P. aeruginosa and 
mediating passive immunity in mice than serum raised to 
flagellin. This was attributed to flagellin inducing high titres 
of antibodies which could neutralise the innate immunity due 
to TLR5 activation [49]. 
 Combinations of both outer membrane proteins OprF and 
OprI and flagellins have also been evaluated in a multimeric 
fusion protein vaccine, in order to further optimise the pro-
tective host response by exploiting the ability of flagellin to 
activate TLR-5 and act as an adjuvant as well as an antigen 
[50]. Immunisation of mice with a combination of an OprF 
epitope fused with OprI incorporated at the N-terminus of 
the type A or type B flagellin resulted in high level of anti-
bodies to OprF, flagellin and OprI. The Opr/flagellin recom-
binant proteins elicited high titres of IgG2a, in addition to 
IgG1, although the response was biased towards a Th1 re-
sponse. In addition, immunisation reduced the bacterial bur-
den in mice challenged with non-mucoid P. aeruginosa 
strains. One limitation of this study was that although anti-
gen specific antibodies were able to activate complement, 
complement-mediated killing was only effective against non-
mucoid bacteria, being less effective against mucoid bacte-
ria. The conversion of P. aeruginosa to a mucoid phenotype 
during chronic infection which may have significant impacts 
on the exposure and expression of surface antigens and is 
likely to be an additional challenge in developing effective 
vaccines to protect against this pathogen.  
 There are considerable advances yet to be made both in 
our knowledge of the host response and in the development 
of an effective vaccine for this difficult pathogen, again 
demonstrating that antigen identification is only a fraction of 
the process to a successful vaccine. These studies also high-
light the limitations of immunoproteomics to predict good
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Table 1.  Examples of Immunoproteomics Studies to Identify Vaccine Antigens and/or Virulence Factors in Respiratory Pathogenic 
Bacteria 
Pathogen # Antigen(s) of interest Serum source Protein fraction Protective Comment Ref 
Bd. pertussis 30 
Pertactin, serum resistance protein 
(BrkA), OmpP, sulphate binding protein 
(Sbp) 
Immunised chil-
dren (whole cell 
pertussis vac-
cine) 
Total membrane 
proteins & ex-
tracellular pro-
teins 
NA 
Observed differ-
ences between 
mouse and hu-
man serum data 
[35] 
Bd. pertussis 1 Peptidoglycan associated lipoprotein Immunised mice Cell lysate NA 
immunodomi-
nant antigen 
[62] 
Bd. pertussis 25 
Serum resistance protein, pertactin, HSP-
60, HSP70,Clp protease, serine protease, 
EF-Tu, Glutamyl-tRNA aminotrans-
ferase, phosphoenolpyruvate synthase 
Immunised mice Soluble proteins NA 
Comparison of 
two vaccine 
strains 
[34] 
Bd. pertussis 11 
Serum resistance protein, pertactin, sero-
type fimbral subunit, HSP-60, HSP-10, 
ATP synthase 
Immunised mice Surface proteins NA 
Comparison of 
two vaccine 
strains 
[33] 
B. cepacia 18 
EF-Tu, pyruvate carboxylase, ATP-
dependent zinc metalloprotease, tyrosyl-
tRNA synthase, phospholipid glycerol 
acyltransferase, ABC efflux pump 
Immunised mice Secreted proteins NA  [27] 
B. pseudomallei 12 
GroEL, DnaK, PhaP, Ef-Tu, polyribonu-
cleotide nucleotidyltransferase 
Immunised rab-
bit serum 
Surface proteins NA 
9 Antigens both 
biotinylated and 
immunoreactive 
[14] 
B. thailandensis 16 
Ef-Tu, DnaK, AhpC, oxodipate CoA 
succinyltransferase, HSP10, 
Rabbit from B. 
mallei immu-
nised rabbits 
 Protection 
EF-Tu 
immunoprotec-
tive 
[63] 
F. tularensis 31 
F1F0 ATP synthase, EF-Tu, glutamylt-
RNA synthase, fructose bisphosphateal-
dolase, GAPDH, pyruvate dehydro-
genase, DnaK 
Tularemia pa-
tients and vacci-
nated individuals 
 NA  [64] 
F. tularensis 9 
EF-Tu, GroEL, ATP synthase, DNA 
gyrase, chitinase family 18 protein, DNA 
directed RNA polymerase 
Mouse sera from 
Live attenuated 
immunised mice 
Soluble and 
membrane en-
riched 
NA 
Comparison of 
responses from 
successful vac-
cination and 
unsuccessful 
vaccination – 
examples of 
successful vac-
cination in bold. 
[65] 
Leptospira 
interrogans 
 Lipoprotein L21, L41, L32. Loa22. Rat infection 
Membrane pro-
teins, in vitro 
culture and 
guinea pig infec-
tion 
NA  [66] 
P. aeruginosa 51 
PasP protease, zinc dependent aminopep-
tidase, azurin, OprH, LasB protease, 
PrpL protease 
CF patient sera Extracellular NA 
Compared 2 
strains, PA01 
and PA14 
[51] 
N. meningitidis 33 
TufA (EF-Tu), alcohol dehydrogenase, 
DnaK, cysteine synthase, aconitasehy-
dratase, ATP synthase F1, Opa900 
Convalescent 
patients 
Total protein 
No serum 
bacterici-
dal anti-
bodies 
produced 
 [29] 
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(Table 1) Contd…. 
Pathogen # Antigen(s) of interest Serum source Protein fraction Protective Comment Ref 
S. pneumoniae 17 
Glutamyl-
tRNAamidotransferase,GAPDH, 
fructose bis-phosphate aldolase, 6-
PGD 
Healthy chil-
dren and adults 
(asymptomatic 
carriage) 
Surface proteins 
4 tested, all 
showed 
protection 
 [9-11] 
S. pneumoniae 23 
Enolase, serine protease, N-
acetylglucosamine-6-phosphate 
deacetylase, general stress protein, 
pneumococcal histidine triad pro-
tein D precursor , Zinc metallopro-
tease 
Immunised 
rabbits 
Secreted proteins 
No in vivo 
studies 
All 6 listed immunore-
active proteins found in 
all 3 clinical strains 
tested. 
[13] 
# Number of antigens identified.  
vaccine antigens. Although flagellin type B protein (FliC) 
was identified in an immunoproteomics analysis of extracel-
lular P. aeruginosa proteins using CF patient serum [51], 
confirming its potential to produce high antibody titres; nei-
ther OprF nor OprI were identified in this study. The authors 
attributed the presence of flagellin and other OMPs among 
extracellular immunogens to bacterial cell lysis. However, 
OprF and OprI would also be expected to be present in a 
bacterial lysate. Their lack of detection in this study could 
suggest that they were not released from the cell surface, 
under the conditions tested, or like certain Bd. pertussis anti-
gens these may not be amenable to detection by immunopro-
teomics.  
CONCLUSIONS 
 Examples of immunoreactive proteins identified by im-
munoproteomics in a range of respiratory pathogens are 
listed in (Table 1). Many of these are common across several 
unrelated bacteria. For example, GroEL (HSP60) and DnaK 
(HSP70), are both conserved heat shock proteins and are 
highly immunoreactive in several diverse pathogens includ-
ing Shigella flexineri, Helicobacter pylori and Yersinia en-
tercolitica [52-54]. Immunisation with GroEL, but not DnaK 
resulted in 100% protection in mice following Bacillus an-
thracis challenge [55]. GroEL immunisation was also protec-
tive against S. pneumoniae [56]. EF-Tu is another antigen 
which is immunoreactive across several pathogens. Interest-
ingly, while it was protective against B. thailandensis, it was 
not protective when used in immunisation studies followed 
by challenge with N. meningitidis. In addition, it was among 
the immunoreactive proteins that were identified with serum 
from both successfully and unsuccessfully vaccinated mice 
using an attenuated Francisella tularensis vaccine strain, 
suggesting that antibodies against EF-Tu are not protective 
against this pathogen [65]. EF-Tu has been shown to bind to 
host proteins such as fibronectin, mucin and plasminogen 
[57-59] and as a result may play a direct role in the microbial 
host response for certain pathogens. This may be an impor-
tant criterion in discerning the most protective antigens 
among all those identified in an immunoproteomics study. 
Immunoreactogenicity needs to be considered alongside the 
potential pathogenicity of any individual protein, as protec-
tive vaccine antigens tend to be those that play a role in 
pathogenesis. Many immunoreactive proteins identified in 
the studies outlined here are metabolic enzymes and would 
be considered to have a cytoplasmic localisation within the 
cell. The fact that they are immunogenic during infection in 
animals and patients, could be due to bacterial cell lysis or 
could be due to these enzymes having as yet an undeter-
mined role in bacterial virulence and are worthy of further 
study.  
 In summary, the advances in immunoproteomics have led 
to a massive increase in the potential vaccine candidates 
which may be useful to protect against difficult to treat bac-
terial pathogens. While this review has focussed on respira-
tory pathogens, many immunoreactive antigens have also 
been identified using this approach for other bacterial patho-
gens, e.g. Staphylococcus epidermidis [60], Campylobacter 
concisus [61]. As outlined, this potent technology is not 
without limitations, but when used with serum from either 
colonised or convalescent patients, it is particularly useful as 
it allows researchers to identify immunoreactive antigens 
that are expressed during human infection. Further thorough 
examination of the host immune response, including immu-
nisation studies in a number of carefully selected models, 
will help identify which of the immunogenic proteins can be 
taken further to human trials. It is likely that multivalent vac-
cines can be developed by careful selection of immunoreac-
tive antigens identified with immunomic technologies and 
when combined with the appropriate adjuvant will increase 
our weaponry in the defence against respiratory bacterial 
infections.  
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